Get the Stockscreener App
0.32
3.79%
-0.0126
Marinus Pharmaceuticals Inc stock is traded at $0.32, with a volume of 587.10K.
It is down -3.79% in the last 24 hours and down -82.02% over the past month.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
See More
Previous Close:
$0.3326
Open:
$0.3326
24h Volume:
587.10K
Relative Volume:
0.26
Market Cap:
$18.02M
Revenue:
$30.99M
Net Income/Loss:
$-141.41M
P/E Ratio:
-2.1333
EPS:
-0.15
Net Cash Flow:
$-118.12M
1W Performance:
+10.34%
1M Performance:
-82.02%
6M Performance:
-78.81%
1Y Performance:
-95.42%
1-Day Range:
$0.3177
$0.3326
1-Week Range:
$0.2875
$0.3458
52-Week Range:
$0.2603
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Name
Marinus Pharmaceuticals Inc
Sector
Industry
Phone
484-801-4670
Address
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-23 | Initiated | RBC Capital Mkts | Outperform |
| Sep-30-20 | Initiated | Truist | Buy |
| Jul-01-20 | Initiated | Cowen | Outperform |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-09-20 | Initiated | Craig Hallum | Buy |
| Dec-20-19 | Initiated | Oppenheimer | Outperform |
| Mar-05-19 | Resumed | Jefferies | Buy |
| Feb-27-19 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-19 | Initiated | Leerink Partners | Outperform |
| Jul-02-18 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-20-18 | Initiated | Mizuho | Buy |
| Feb-15-18 | Initiated | H.C. Wainwright | Buy |
| Dec-14-17 | Initiated | Laidlaw | Buy |
| Aug-10-16 | Reiterated | Jefferies | Buy |
| Jun-14-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-08-16 | Reiterated | Stifel | Buy |
| Dec-17-15 | Initiated | RBC Capital Mkts | Outperform |
| Nov-17-15 | Initiated | Jefferies | Buy |
| Oct-30-15 | Reiterated | Oppenheimer | Outperform |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
View All
Marinus Pharmaceuticals Inc Stock (MRNS) Latest News
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
Marinus downgraded after setback to late-stage trial - MSN
Marinus Pharmaceuticals Hosts Investor and Analyst Day - MSN
TD Cowen Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal - MSN
Marinus Pharmaceuticals (MRNS) Halts Ganaxolone Development for TSC After Phase 3 Trial Failure - BP Journal
Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent - MSN
Marinus Pharmaceuticals price target lowered to $1 from $3 at RBC Capital - TipRanks
Marinus stock downgraded after trial setback (MRNS:NASDAQ) - Seeking Alpha
HC Wainwright Reiterates "Neutral" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS) - MarketBeat
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo! Voices
Marinus Pharma Halts Development After Seizure Drug Fails Trial - Medical Dialogues
JMP Securities Downgrades Marinus Pharmaceuticals (MRNS) - MSN
Marinus halts ganaxolone development after trial setback - Investing.com India
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 - Investing.com India
Marinus Pharmaceuticals downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Marinus Pharma to hold, slashes target to $0.50 By Investing.com - Investing.com UK
Marinus halts ganaxolone development after trial setback By Investing.com - Investing.com Australia
Truist cuts Marinus Pharma to hold, drops price target - Investing.com
Truist cuts Marinus Pharma to hold, drops price target By Investing.com - Investing.com UK
Baird cuts Marinus Pharma target to $0.50 on failed study - Investing.com
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options - AOL
Marinus Pharmaceuticals price target lowered to 50c from $2 at Baird - TipRanks
Marinus Pharmaceuticals downgraded to Market Perform at JMP Securities - TipRanks
Marinus to trim workforce, weigh 'strategic alternatives' after another Ztalmy trial miss sends shares tumbling - FiercePharma
Marinus Pharma stock plunges to 52-week low of $0.52 - Investing.com
Marinus hits record low after discontinuing development of rare disease drug - XM
Marinus Pharma stock plunges to 52-week low of $0.52 By Investing.com - Investing.com Canada
Marinus Pharmaceutical Shares Plumb New Depths After Study Failure - MarketWatch
Marinus Therapeutics plans layoffs, explores strategic alternatives as shares sink - The Business Journals
Marinus Pharma to explore options as rare disease drug fails trial - XM
Marinus notes TrustTSC trial misses primary endpoint, to evaluate alternatives - TipRanks
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - Business Wire
Marinus Pharmaceuticals Issues Stock Options to New Employee - MSN
Marinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status Epilepticus - MSN
Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment - Clinical Trials Arena
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting - BioSpace
MRNSMarinus Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Marinus reports positive phase 3 seizure treatment trial results - Investing.com
Marinus reports positive phase 3 seizure treatment trial results By Investing.com - Investing.com Australia
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens - BioSpace
Marinus Pharmaceuticals secures new US patent for epilepsy drug By Investing.com - Investing.com Australia
Marinus Pharmaceuticals secures new US patent for epilepsy drug - Investing.com
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY - Business Wire
Examining Marinus Pharmaceuticals Inc (MRNS) more closely is necessary - US Post News
Marinus Pharmaceuticals Inc Stock (MRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Marinus Pharmaceuticals Inc Stock (MRNS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Aug 05 '24 |
Sale |
1.14 |
3,820 |
4,355 |
67,406 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Aug 05 '24 |
Sale |
1.13 |
3,621 |
4,092 |
60,263 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Aug 05 '24 |
Sale |
1.13 |
4,828 |
5,456 |
72,725 |
| Braunstein Scott | CHAIRMAN AND CEO |
Aug 05 '24 |
Sale |
1.13 |
12,145 |
13,724 |
298,667 |
| Braunstein Scott | CHAIRMAN AND CEO |
Mar 27 '24 |
Option Exercise |
4.28 |
50,000 |
214,000 |
273,512 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Feb 20 '24 |
Sale |
9.56 |
2,153 |
20,583 |
60,308 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Feb 20 '24 |
Sale |
9.57 |
1,894 |
18,126 |
52,966 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Feb 16 '24 |
Sale |
9.98 |
2,814 |
28,084 |
66,635 |
| Pfanstiel Steven | CFO AND COO |
Feb 16 '24 |
Sale |
9.97 |
3,092 |
30,827 |
71,697 |
| Braunstein Scott | CHAIRMAN AND CEO |
Feb 16 '24 |
Sale |
9.94 |
11,850 |
117,789 |
223,512 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):